Diamond Biofund teams up with suppliers to create sustainable enterprises. “The Supplier CSR Commitment Letter” has been formulated with reference to the related international initiatives and requirements, including the UN Global Compact, the Universal Declaration of Human Rights, and the UN Framework and Guiding Principles on Business and Human. All the suppliers are required to sign the Letter. The main contents of the Letter include the following sustainability-related items:
In 2024, the “Supplier Management Procedures” were revised, and a new supplier self-assessment questionnaire was introduced. The updated supplier evaluation form now includes ESG assessment items such as environmental protection, labor conditions, human rights, and corporate governance, alongside the original criteria of cooperation, delivery times, raw material quality, and quality systems. These criteria will be used to assess supplier risks. The new evaluation was officially implemented in the second half of 2024, and the results will serve as a key basis for Diamond Biofund’s future procurement strategy. For high-risk suppliers, Diamond Biofund will further investigate and conduct site visits, provide recommendations, and assist in improvements, working together with suppliers to create a sustainable environment.
By the end of 2025, five suppliers had completed the “Sustainability Risk Assessment and Evaluation”. Due to the Company’s investment business and belongs to general office environment, these suppliers mainly included vendors providing office equipment, IT hardware and software, and event-related services.
醣基生醫股份有限公司
2017年9月27日登錄興櫃市場交易 (6586:TT)
公司所在地
台北，台灣
公司設立日期
2013
登錄公開市場
2017
公司官網
https://www.chopharma.com/cn/index.html
